B of A Securities analyst Geoff Meacham reinstates Gilead Sciences (NASDAQ:GILD) with a Neutral and announces $85 price target.
B of A Securities Reinstates Neutral on Gilead Sciences, Announces $85 Price Target
B of A Securities analyst Geoff Meacham reinstates Gilead Sciences (NASDAQ:GILD) with a Neutral and announces $85 price target.
Related Posts
Finetwork Selects Amdocs To Modernize Its Systems, Enabling Spanish Operator To Provide Fiber, TV, And Mobile Services
Amdocs' AI-based Digital Brands Suite as a Service, powered by AWS, will empower Finetwork to enhance its offerings and provide end users with a simpler, digital customer experienceJERSEY CITY, NJ / ACCESSWIRE / February
A Look Into ING Groep Inc’s Price Over Earnings
Looking into the current session, ING Groep Inc. (NYSE:ING) shares are trading at $12.89, after a 1.15% drop.…
EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
Alzamend Neuro Inc (NASDAQ: ALZN) has received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for